CCTA-1523

Research use only, not for human use.

CCTA-1523 is an efflux function of ABCG2 inhibitor. CCTA-1523 selectively reverses ABCG2-mediated MDR in cancer cells.

CCTA-1523 is an efflux function of ABCG2 inhibitor. CCTA-1523 selectively reverses ABCG2-mediated MDR in cancer cells.(In Vitro):CCTA-1523 (5μM) sensitized the ABCG2 overexpressing cancer cells and ABCG2 transfected cells to the substrate chemotherapeutic drugs.(In Vivo):Co-administration of CCTA-1523 restored the in vivo antitumor activity of doxorubicin in ABCG2 overexpressing tumor xenografts.

——

Animal Model:NCR nude mice (H460/MX20 xenografts) Dosage:75 mg/kg (DOX ;1.8 mg/kg, i.p., q3d X 6 ) Administration:P.o.;q3d x 6 Result:Significantly inhibited the growth of H460/MX20 tumor xenografts when combined with doxorubicin compared to the vehicle control group.

——

Others

Other Targets

——

——

——

1616271-41-0

340.2

C16H15Cl2NO3

>98% (HPLC)

——

COc(ccc(-c1cccc(NC(C(Cl)Cl)=O)c1)c1)c1OC

——

(-20℃)

With Ice Pack

≥ 2 years